Special Issue "Liquid Biopsy for Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 15 May 2019
The current gold standard for cancer diagnosis remains the histological examination of invasively obtained biopsy tissue. This technique is sometimes risky, often difficult to perform, expensive, slow, and uncomfortable for the patient. As a consequence, there has been a great deal of interest in non-invasive biomarkers in biological fluids such as blood, urine, and saliva. So-called “liquid biopsies” are more economical, rapid, and easy to perform than current clinical protocols. Most importantly, liquid biopsies represent a paradigm shift in cancer patient management, as the ability to carry out repeat sampling permits for the first time the real-time monitoring of patient treatment response and disease progression, allowing for earlier intervention and dynamic treatment management, and therefore a more personalized approach. Moreover, there is an increasing awareness of the molecular heterogeneity of tumors and a realization that traditional tissue biopsies may miss this diversity. In contrast, liquid biopsies can capture the entire molecular panorama of the tumoral landscape. Furthermore, liquid biopsies are eminently suitable for use in screening programs.
In recognition of the potential of this field, in recent years there has been much interest in the field of circulating nucleic acids. Circulating DNA research which has its origins in the 1940s has recently been focused on the detection of cancer-associated mutations and other chromosomal aberrations. This research is now translating into the clinic, initially with EGFR mutation testing in lung cancer. In contrast, the field of circulating RNA was largely neglected after its initial discovery nearly 20 years ago, as the high levels of RNase present in blood and other biological fluids were believed to render these labile molecules useless. However, the recent discovery of circulating non-coding RNA, specifically circulating miRNAs, that are resistant to RNase activity has provided fresh impetus for this field.
This Special Issue welcomes original research concerning the discovery and/or validation of circulating biomarkers (nucleic acids or other molecules) in cancer, as well as reviews that critically provide an informative overview of the field.
Prof. Charles Lawrie
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- liquid biopsies
- non-coding RNA
- circulating transcriptome